Compare Gilead Sciences, Inc. (GILD) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $134.5 (market cap $163.51B), while Vanguard Total International Stock Index Fund ETF trades at $84.04. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | VXUS | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $87.06 |
52-Week Low | $108.22 | $68.24 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
VXUS trades at $83.96, down 0.83% on the day, with a bullish technical signal driven by moving averages. The ETF provides broad international stock exposure across developed and emerging markets, with over 8,700 holdings. Recent news highlights its role in diversification and cost efficiency compared to peers.
The outlook for VXUS hinges on global equity performance relative to the US, with potential upside from valuation discounts. Risks include persistent inflation and growth concerns outside the US. Analyst sentiment is mixed, with some caution due to macroeconomic headwinds affecting international markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
